Canada Markets closed

LexaGene Holdings Inc. (LXG.V)

TSXV - TSXV Delayed Price. Currency in CAD
Add to watchlist
0.98000.0000 (0.00%)
At close: 3:59PM EDT
Full screen
Previous Close0.9800
Open0.9800
Bid0.9600 x 0
Ask0.9800 x 0
Day's Range0.9700 - 0.9900
52 Week Range0.4300 - 1.2800
Volume254,863
Avg. Volume238,273
Market Cap90.047M
Beta (5Y Monthly)2.41
PE Ratio (TTM)N/A
EPS (TTM)-0.0970
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    49 Public Companies to Present at the SNN Network Virtual Conference - August 3-6, 2020

    LOS ANGELES, CA / ACCESSWIRE / August 3, 2020 / The SNN Network Virtual Conference will take place on August 3rd \\- 6th, 2020, where 49 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.

  • GlobeNewswire

    Testing’s Critical Role in Stemming the Tide

    NEW YORK, July 22, 2020 (GLOBE NEWSWIRE) -- via NetworkWire — LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 40+ brands in the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.To view the full publication, “Breakthroughs and Advancements in Pathogen Detection Offer Hope as Virus Cases Surge,” visit: http://nnw.fm/eTKlySetting a new standard in testing, LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF) (LXG Profile) has developed a unique pathogen detection instrument—a fully automated genetic analyzer used to rapidly identify multiple pathogens, bacteria, and viruses including COVID-19. LexaGene’s breakthrough technology is highly accurate, designed to be used at sample collection sites, and can deliver test results on 27 pathogens and/or antimicrobial resistance factors at once in about an hour. LexaGene is already working with the FDA on its submission plan for Emergency Use Authorization (EUA) for COVID-19 testing.Testing is the first and foremost tool in the fight against the coronavirus. But with cases in the US and around the world skyrocketing, the need for faster, more accurate tests is urgent. Public health experts across the globe agree that early detection is paramount to controlling the spread of the disease. Fast, accurate testing allows for contact tracing and isolating infections to stop rampant spread, but the country is falling short on testing as demand for tests far outstrips supply and availability.About LexaGene Holdings Inc.LexaGene is a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press ‘go’. The LX Analyzer delivers excellent sensitivity, specificity, and breadth of detection and can return results in about 1 hour. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.About NetworkNewsWireNetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 40+ brands within our InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.For more information, please visit: https://www.NetworkNewsWire.comPlease see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/DisclaimerForward-Looking StatementsThis release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.Corporate Communications: NetworkNewsWire (NNW) New York, New York www.NetworkNewsWire.com 212.418.1217 Office Editor@NetworkNewsWire.com

  • GlobeNewswire

    LexaGene to Host Webcast on July 14, 2020

    LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops genetic analyzers for rapid pathogen detection, is pleased to announce that it will host a webcast investor presentation on Tuesday, July 14, at 2:00 PM ET. During the webcast, Dr. Jack Regan, LexaGene’s CEO and Founder, will provide an introductory presentation through a PowerPoint discussion that will cover key areas of LexaGene’s business, including an overview of the Company’s proprietary technology, target markets and opportunity, competitive advantages, growth strategy, and anticipated milestones. Following the formal presentation, investors will have an opportunity to ask relevant questions through an interactive Q&A portal.